References

Arshad, M. I., Khan, H. A., Noel, G., Piquet-Pellorce, C., & Samson, M. (2016). Potential Therapeutic Aspects of Alarmin Cytokine Interleukin 33 or Its Inhibitors in Various Diseases. *Clinical Therapeutics*, *38*(5), 1000-1016.e1.

Burns Alistair, Iliffe Steve. Alzheimer's Disease BMJ 2009;338: b158

Burns Alistair, Iliffe Steve. Dementia BMJ 2009;338: b75

Cao, K., Liao, X., Lu, J., Yao, S., Wu, F., Zhu, X., … Zhou, H. (2018). IL-33/ST2 plays a critical role in endothelial cell activation and microglia-mediated neuroinflammation modulation. *Journal of Neuroinflammation*, *15*(1), 1–12.

Filali, M., & Lalonde, R. (2009). Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. *Brain Research*, *1292*, 93–99. https://doi.org/10.1016/j.brainres.2009.07.066

Fitsiori, A., Nguyen, D., Karentzos, A., Delavelle, J., & Vargas, M. I. (2011). The corpus callosum: White matter or terra incognita. *British Journal of Radiology*, *84*(997), 5–18.

Fu, A. K., Hung, K. W., Yuen, M. Y., Zhou, X., Mak, D. S., Chan, I. C., Cheung, T. H., Zhang, B., Fu, W., Liew, F. Y. & Ip, N. Y. (2016). IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proceedings of the National Academy of Sciences, 113(19), E2705-E2713.

Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S.M., Bacskai, B. J., & Frosch, M. P. (2006). Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiology of disease, 24(3), 516-524.

Goel, M. K., Khanna, P., & Kishore, J. (2010). Understanding survival analysis: Kaplan-Meier estimate. IJAR (International Journal of Ayurveda Research), 1(4), 274–278.

Griesenauer, B., & Paczesny, S. (2017). The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Frontiers in Immunology,8.

Hansen, D. V., Hanson, J. E., & Sheng, M. (2018). Microglia in Alzheimer's disease. The Journal of cell biology, 217(2), 459-472.

Huang, H., Nie, S., Cao, M., Marshall, C., Gao, J., Xiao, N., … Xiao, M. (2016). Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice. *Age*, *38*(4), 303–322.

Isnadi, M. F., Chin, V. K., Majid, R. A., Lee, T. Y., Abdullah, M. A., Omenesa, R. B., &Basir, R. (2018). Critical Roles of IL-33/ST2 Pathway in Neurological Disorders. Mediators of Inflammation,2018, 1-9.

Jacobs, H. I. L., Hopkins, D. A., Mayrhofer, H. C., Bruner, E., Van Leeuwen, F. W., Raaijmakers, W., & Schmahmann, J. D. (2018). The cerebellum in Alzheimer's disease: Evaluating its role in cognitive decline. *Brain*, *141*(1), 37–47.

Jahn-Eimermacher, A., Lasarzik, I., & Raber, J. (2011). Statistical analysis of latency outcomes in behavioral experiments. Behavioural Brain Research, 221(1), 271–275.

Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., & Borchelt, D. R. (2001). Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular engineering, 17(6), 157-165.

Janus, C., Flores, A. Y., Xu, G., & Borchelt, D. R. (2015). Behavioral abnormalities in APPSwe/PS1dE9 mouse model of AD-like pathology: comparative analysis across multiple behavioral domains. Neurobiology of aging, 36(9), 2519-2532

Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2009). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 35(4), 870-80.

Kumar, A., Singh, A., & Ekavali. (2015). A review on Alzheimers disease pathophysiology and its management: An update. Pharmacological Reports,67(2), 195-203.

Lalonde, R., Kim, H. D., Maxwell, J. A., & Fukuchi, K. (2005). Exploratory activity and spatial learning in 12-month-old APP695SWE/co+ PS1/ΔE9 mice with amyloid plaques. Neuroscience letters, 390(2), 87-92.

Lane, C. A., Hardy, J. and Schott, J. M. (2018), Alzheimer's disease. Eur J Neurol, 25: 59-70.

Liew, F. Y., Girard, J., & Turnquist, H. R. (2018). Interleukin-33 in health and disease. Nature Reviews Immunology,16, 676-689.

Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2008; 28 (51):13805–14. Epub 2008/12/19.

Malm, T., Koistinaho, J., & Kanninen, K. (2011). Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications. International journal of Alzheimer's disease, 2011, 517160.

Miller A. M. (2011). Role of IL-33 in inflammation and disease. Journal of inflammation (London, England), 8(1), 22.

Minkeviciene, R., Rheims, S., Dobszay, M. B., Zilberter, M., Hartikainen, J., Fülöp, L., Penke, B., Zilberter, Y., Harkany, T., Pitkänen, A., & Tanila, H. (2009). Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. Journal of Neuroscience, 29(11), 3453-3462.

Montgomery, W., Ueda, K., Jorgensen, M., Stathis, S., Cheng, Y., & Nakamura, T. (2017). Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan. ClinicoEconomics and outcomes research: CEOR, 10, 13-28.

Nguyen, K. V. (2018). Special Issue: Alzheimer's disease. AIMS Neuroscience, 5(1), 74-80

Olesen, L. Ø., Bouzinova, E. V., Severino, M., Sivasaravanaparan, M., Hasselstrøm, J. B., Finsen, B., & Wiborg, O. (2016). Behavioural phenotyping of APPswe/PS1δE9 mice: Age-rrelated changes and effect of long-term paroxetine treatment. *PLoS ONE*, *11*(11), 1–21.

Pascual-Figal, D. A., & Januzzi, J. L. (2015). The biology of ST2: the international ST2 consensus panel. The American journal of cardiology, 115(7), 3B-7B.

Patterson, C. (2018). The state of the art of dementia research: New frontiers. World Alzheimer Report 2018.

Ricciarelli, R., & Fedele, E. (2017). The amyloid cascade hypothesis in Alzheimer's disease: it's time to change our mind. Current Neuropharmacology, 15(6), 926-935.

Rosenberg RN, Lambracht-Washington D, Yu G, Xia W. (2016). Genomics of Alzheimer Disease: A Review. JAMA Neurol. 2016;73(7):867–874.

Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017). APP mouse models for Alzheimer's disease preclinical studies. The EMBO journal, 36(17), 2473-2487.

Sumiyoshi, A., Taki, Y., Nonaka, H., Takeuchi, H., & Kawashima, R. (2014). Regional gray matter volume increases following 7days of voluntary wheel running exercise: A longitudinal VBM study in rats. *NeuroImage*, *98*, 82–90.

Szapacs, M. E., Mathews, T. A., Tessarollo, L., Ernest Lyons, W., Mamounas, L. A., & Andrews, A. M. (2004). Exploring the relationship between serotonin and brain-derived neurotrophic factor: Analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. *Journal of Neuroscience Methods*, *140*(1-2 SPEC. ISS.), 81–92.

Van Eldik, L. J., Carrillo, M. C., Cole, P. E., Feuerbach, D., Greenberg, B. D., Hendrix, J. A., Kennedy, M., Kozauer, N., Margolin, R. A., Molinuevo, J. L., Mueller, R., Ransohoff, R. M., Wilcock, D. M., Bain, L., & Bales, K. (2016). The roles of inflammation and immune mechanisms in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2(2), 99-109.

Vincent, T. J., Thiessen, J. D., Kurjewicz, L. M., Germscheid, S. L., Turner, A. J., Zhilkin, P., … Martin, M. (2010). Longitudinal Brain Size Measurements in App/Ps1 Transgenic Mice. *Magnetic Resonance Insights*, *4*, MRI.S5885.

Wang, J., Gu, B. J., Masters, C. L., & Wang, Y. (2017). A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain. Nature Reviews Neurology,13(10), 612-623.

Weller J and Budson A. Current understanding of Alzheimer's disease diagnosis and treatment [version 1; peer review: 2 approved]. F1000Research 2018, 7(F1000 Faculty Rev):1161

Wen, X., Wu, X., Li, R., Fleisher, A. S., Reiman, E. M., Wen, X., … Yao, L. (2013). Alzheimer's disease-related changes in regional spontaneous brain activity levels and inter-region interactions in the default mode network. *Brain Research*, *1509*, 58–65.

Xiong, Z., Thangavel, R., Kempuraj, D., Yang, E., Zaheer, S., & Zaheer, A. (2014). Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. Journal of Alzheimer's disease: JAD, 40(2), 297-308.

Zerbi, V., Kleinnijenhuis, M., Fang, X., Jansen, D., Veltien, A., Van Asten, J., … Heerschap, A. (2013). Gray and white matter degeneration revealed by diffusion in an Alzheimer mouse model. *Neurobiology of Aging*, *34*(5), 1440–1450.

Jefferson, A. L., Gifford, K. A., Damon, S., Chapman, G. W., 4th, Liu, D., Sparling, J., … Alzheimer's Disease Neuroimaging Initiative (2015). Gray & white matter tissue contrast differentiates Mild Cognitive Impairment converters from non-converters. *Brain imaging and behavior*, *9*(2), 141–148. doi:10.1007/s11682-014-9291-2

Chen, Y. F., & Chen, Y. S. (2016). Is the grey-to-white ratio valuable enough in prediction for cardiac arrest patients rescued with extracorporeal resuscitation?. *Journal of thoracic disease*, *8*(6), E469–E470. doi:10.21037/jtd.2016.04.26

Eldik, L. J., Carrillo, M. C., Cole, P. E., Feuerbach, D., Greenberg, B. D., Hendrix, J. A., … Bales, K. (2016). The roles of inflammation and immune mechanisms in Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, *2*(2), 99–109.

Verkhratsky, A., Verkhratsky, A., Olabarria, M., Noristani, H. N., & Yeh, C. (2010). Astrocytes in Alzheimer ' s Disease Astrocytes in Alzheimer ' s Disease. *Nurt*, *7*(4), 399–412.

Vainchtein, I. D., Chin, G., Cho, F. S., Kelley, K. W., Miller, J. G., Chien, E. C., … Molofsky, A. V. (2018). *and Neural Circuit Development*. *1273*(March), 1269–1273.

Fairlie-Clarke, K., Barbour, M., Wilson, C., Hridi, S. U., Allan, D., & Jiang, H. R. (2018). Expression and function of IL-33/ST2 axis in the central nervous system under normal and diseased conditions. *Frontiers in Immunology*, *9*(NOV), 8–11.

Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., … Barres, B. A. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*, *541*(7638), 481–487. doi:10.1038/nature21029